The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Associations between ECOG performance status (PS) and patient-reported outcomes (PROs) in patients with gastric or gastroesophageal junction (G/CEJC) adenocarcinoma: Results from the RATIONALE-305 trial.
 
Marcia Cruz-Correa
Employment - Pan American Center for Oncology Trials
Stock and Other Ownership Interests - Pan American Center for Oncology Trials
Research Funding - Abbvie (Inst); BeiGene (Inst); Bristol-Myers Squibb/Celgene (Inst); Genentech/Roche (Inst); GENFIT (Inst); HUYA Bioscience International (Inst); Janssen (Inst); Lilly (Inst); Merck (Inst); Pfizer (Inst); Regeneron (Inst); VMO (Inst)
Patents, Royalties, Other Intellectual Property - Licencing agreement with Johns Hopkins University on technology.
 
Markus Moehler
Honoraria - Amgen; Astellas Pharma; AstraZeneca/MedImmune; Bayer Schering Pharma; Bristol-Myers Squibb; Daiichi Sankyo Europe GmbH; Idience; Merck Serono; MSD Oncology; Pierre Fabre; Transcenta; Triptych Health Partners
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; BeiGene; BMS; Daiichi Sankyo Europe GmbH; Lilly; Merck Serono; MSD; SERVIER; Taiho Pharmaceutical; Takeda
Research Funding - Amgen (Inst); AstraZeneca (Inst); Leap Therapeutics (Inst); Merck Serono (Inst); MSD (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Amgen; ASCO; Bayer; BeiGene; ESMO; German Cancer Society; Merck Serono; MSD; Roche; Sanofi Pasteur
 
Crystal Denlinger
Employment - National Comprehensive Cancer Network
Leadership - National Comprehensive Cancer Network
Research Funding - 2seventy bio (Inst); Abbvie (Inst); Bluebird Bio (Inst); Bristol Myers Squibb (Inst); Genentech Foundation (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Merck (Inst); Pfizer (Inst); Sanofi (Inst)
 
Ken Kato
Honoraria - BMS; Lilly; Ono Pharmaceutical
Consulting or Advisory Role - AstraZeneca; BeiGene; Chugai Pharma; Daiichi Sankyo/UCB Japan; MSD; Oncolys BioPharma; Ono Pharmaceutical
Speakers' Bureau - Bristol-Myers Squibb Japan; MSD; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); Beigene (Inst); Chugai Pharma (Inst); Daiichi Sankyo/UCB Japan (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst)
 
Afsaneh Barzi
Employment - BeiGene
Leadership - BeiGene; Cardiff Oncology
Stock and Other Ownership Interests - BeiGene
Consulting or Advisory Role - Bayer Technology System; bioTheranostics; Daiichi Sankyo/Astra Zeneca; Merrion
Speakers' Bureau - Helsinn Therapeutics/QED Therapeutics
Research Funding - Bayer (Inst); Merck (Inst)
 
Bryant Barnes
Employment - BeOne Medicines
Stock and Other Ownership Interests - BeOne Medicines
 
Gisoo Barnes
Employment - BeOne Medicines
Stock and Other Ownership Interests - BeOne Medicines
 
Joselyn Angeles-Figueroa
Employment - BeOne Medicines
Stock and Other Ownership Interests - BeOne Medicines
 
Timothy Victor
Employment - BeOne Medicines
Consulting or Advisory Role - BeOne Medicines